BCRX BioCryst Pharmaceuticals, Inc. Stock Quote

BCRX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.28	Insider Own	1.20%	Shs Outstand	179.11M	Perf Week	-7.88%
Market Cap	2.60B	Forward P/E	-	EPS next Y	-0.95	Insider Trans	-14.33%	Shs Float	178.03M	Perf Month	3.03%
Income	-226.80M	PEG	-	EPS next Q	-0.30	Inst Own	59.50%	Short Float	14.65%	Perf Quarter	-2.99%
Sales	114.00M	P/S	22.83	EPS this Y	-16.00%	Inst Trans	1.80%	Short Ratio	7.02	Perf Half Y	-17.33%
Book/sh	-0.82	P/B	-	EPS next Y	18.00%	ROA	-78.10%	Target Price	20.33	Perf Year	55.68%
Cash/sh	1.09	P/C	13.04	EPS next 5Y	17.10%	ROE	261.10%	52W Range	8.37 - 18.48	Perf YTD	2.96%
Dividend	-	P/FCF	-	EPS past 5Y	-13.10%	ROI	-69.30%	52W High	-20.18%	Beta	2.39
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-18.10%	Gross Margin	93.90%	52W Low	76.22%	ATR	1.05
Employees	246	Current Ratio	1.90	Sales Q/Q	572.10%	Oper. Margin	-	RSI (14)	55.15	Volatility	7.28% 7.24%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-25.70%	Profit Margin	-	Rel Volume	0.64	Prev Close	14.26
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 03 BMO	Payout	-	Avg Volume	3.71M	Price	14.75
Recom	2.10	SMA20	3.91%	SMA50	13.40%	SMA200	2.92%	Volume	2,292,806	Change	3.44%

Dec-10-21

Initiated

Oppenheimer

Outperform

$16

Aug-06-21

Downgrade

Jefferies

Buy → Hold

Aug-03-21

Initiated

Cantor Fitzgerald

Overweight

$21

Mar-01-21

Initiated

Cowen

Outperform

$16

Sep-29-20

Resumed

JP Morgan

Overweight

Jun-17-20

Initiated

BTIG Research

Neutral

May-05-20

Upgrade

Barclays

Equal Weight → Overweight

Nov-15-19

Upgrade

BofA/Merrill

Neutral → Buy

$5 → $4

May-24-19

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$16 → $4.50

Nov-16-18

Resumed

Piper Jaffray

Overweight

$15

Aug-08-18

Resumed

JP Morgan

Overweight

Jul-17-18

Upgrade

BofA/Merrill

Underperform → Neutral

Jun-22-18

Initiated

Seaport Global Securities

Neutral

Jan-02-18

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Dec-20-17

Initiated

Barclays

Equal Weight

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

Sep-06-17

Upgrade

JP Morgan

Neutral → Overweight

Sep-06-17

Upgrade

Jefferies

Hold → Buy

Feb-16-17

Initiated

Ladenburg Thalmann

Buy

$11

Aug-12-16

Upgrade

Piper Jaffray

Neutral → Overweight

Jan-24-22 01:37PM	AMC, GME among meme stocks tanking amid market carnage Yahoo Finance Video
Jan-19-22 04:30AM	5 Biotech Stocks That Are Bucking the Selloff Barrons.com
Jan-14-22 04:31AM	Are Institutions Heavily Invested In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares? Simply Wall St.
Jan-13-22 04:20PM	Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week Motley Fool
Jan-11-22 01:48PM	BioCryst Stock at $21 a Share? This Analyst Thinks Its Possible TipRanks +11.16%
11:13AM	BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales Zacks
10:37AM	BioCryst (BCRX) Moves 27.9% Higher: Will This Strength Last? Zacks
Jan-10-22 01:37PM	Why BioCryst Pharmaceuticals Stock Is Jumping on Monday Motley Fool +27.85%
07:00AM	BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance GlobeNewswire
Jan-07-22 09:25AM	BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH GlobeNewswire -6.92%
Jan-04-22 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:00AM	BioCryst to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-21 08:45AM	Theres an Opportunity Brewing in BioCryst Stock, Says Analyst TipRanks
Dec-08-21 06:38PM	Inv Corp Small Cap Value Buys Zuora Inc, Home BancShares Inc, Tegna Inc, Sells Zurn Water ... GuruFocus.com
06:38PM	Inv Corp All America Buys Zuora Inc, Ollie's Bargain Outlet Holdings Inc, Graco Inc, Sells ... GuruFocus.com
Dec-07-21 04:38PM	Mutual of America VIP Small-Cap Value Portfolio Buys Zuora Inc, Home BancShares Inc, BioCryst ... GuruFocus.com +9.21%
04:38PM	Mutual of America VIP All America Portfolio Buys Zuora Inc, Ollie's Bargain Outlet Holdings ... GuruFocus.com
Dec-03-21 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-21 11:18AM	BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930 Zacks
04:14AM	Insider Buying: The BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Senior VP & CFO Just Bought 60% More Shares Simply Wall St.
Nov-29-21 10:00AM	3 Incredibly Cheap Growth Stocks That Could Make You a Millionaire Motley Fool
08:30AM	BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH GlobeNewswire
Nov-23-21 07:21AM	Durham drugmaker scores another cash infusion. This time it's $350 million. American City Business Journals
Nov-22-21 07:10AM	Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals GlobeNewswire
07:00AM	BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets GlobeNewswire
Nov-12-21 07:00AM	BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Nov-05-21 07:00AM	BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat) GlobeNewswire +6.89%
06:26AM	BioCryst: Orladeyo on Track to Reach Top of the HAE Market TipRanks
Nov-03-21 02:31PM	BioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript Motley Fool -18.10%
01:13PM	Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today Motley Fool
08:35AM	BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones GlobeNewswire
Nov-02-21 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-01-21 07:00AM	BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer GlobeNewswire
Oct-27-21 03:04PM	Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-26-21 07:00AM	BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology GlobeNewswire
Oct-25-21 05:23PM	Do Hedge Funds Love BioCryst Pharmaceuticals, Inc. (BCRX)? Insider Monkey +5.17%
Oct-20-21 07:00AM	BioCryst to Report Third Quarter 2021 Financial Results on November 3 GlobeNewswire
Oct-13-21 10:00AM	2 Super-Charged Growth Stocks to Buy Now Motley Fool
Oct-04-21 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-30-21 06:17AM	3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better Motley Fool
Sep-21-21 07:00AM	BioCryst to Present at 2021 Cantor Virtual Healthcare Conference GlobeNewswire
Sep-20-21 07:00AM	BioCryst Appoints Dr. Amy McKee to Board of Directors GlobeNewswire
Sep-16-21 11:50AM	NICE Recommends BioCryst's Hereditary Angioedema Med Benzinga
Sep-15-21 08:20PM	NICE Recommends BioCrysts ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK GlobeNewswire
Sep-09-21 07:00AM	BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates GlobeNewswire
Sep-03-21 07:00AM	BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Sep-02-21 04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-01-21 01:45PM	15 Good Stocks to Buy Right Now Insider Monkey
09:03AM	US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med Benzinga
07:00AM	U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile GlobeNewswire
Aug-26-21 07:00AM	BioCryst Appoints Dr. Steven Galson to Board of Directors GlobeNewswire
Aug-25-21 04:01PM	BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic GlobeNewswire
Aug-23-21 06:47AM	2 Soaring Biotech Stocks With More Fuel in the Tank Motley Fool +6.40%
Aug-10-21 06:55PM	BioCryst Withdraws Public Offering GlobeNewswire -13.85%
Aug-09-21 04:01PM	BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
Aug-06-21 02:31AM	BioCryst Pharmaceuticals (BCRX) Q2 2021 Earnings Call Transcript Motley Fool
01:38AM	What Type Of Shareholders Make Up BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Share Registry? Simply Wall St.
01:20AM	Industry Analysts Just Upgraded Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Revenue Forecasts By 60% Simply Wall St.
Aug-05-21 04:08PM	Why BioCryst Pharmaceuticals Rose 8% on Thursday Motley Fool +8.55%
07:00AM	BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones GlobeNewswire
Aug-03-21 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-28-21 07:00AM	BioCryst Appoints Vincent Milano to Board of Directors GlobeNewswire
Jul-22-21 07:00AM	BioCryst to Report Second Quarter 2021 Financial Results on August 5 GlobeNewswire
Jul-19-21 06:05PM	Is BioCryst Pharmaceuticals, Inc. (BCRX) Going to Burn These Hedge Funds? Insider Monkey
Jul-16-21 06:26AM	Investors Bullish on Biocrysts Pipeline TipRanks
Jul-15-21 09:41AM	BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder Benzinga
07:00AM	BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH GlobeNewswire
Jul-12-21 07:04AM	BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks Benzinga
Jul-10-21 10:00AM	BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline GlobeNewswire
Jul-01-21 04:15PM	ORLADEYO (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress GlobeNewswire
Jun-29-21 07:31AM	Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher? Motley Fool
Jun-16-21 07:00AM	BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO (berotralstat) Marketing Application by the Israeli Ministry of Health GlobeNewswire
Jun-07-21 01:47AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Insiders Increased Their Holdings Simply Wall St. +5.83%
Jun-03-21 07:00AM	BioCryst Launches ORLADEYO (berotralstat) in Germany GlobeNewswire
May-26-21 07:00AM	BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
May-21-21 06:27AM	Is BioCryst a Good Stock to Buy Now? Motley Fool
May-18-21 09:00AM	Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock? Zacks
May-17-21 01:10PM	Why BioCryst Pharmaceuticals Stock Is Jumping Today Motley Fool +11.99%
May-12-21 09:25AM	BioCryst Receives UK Approval of ORLADEYO (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients GlobeNewswire
May-07-21 02:01AM	Strength Seen in BioCryst (BCRX): Can Its 21% Jump Turn into More Strength? Zacks
May-06-21 09:31PM	BioCryst Pharmaceuticals (BCRX) Q1 2021 Earnings Call Transcript Motley Fool +20.97%
11:06AM	Why BioCryst Pharmaceuticals Stock Is Soaring Today Motley Fool
09:05AM	BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones GlobeNewswire
06:30AM	BioCryst Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-05-21 07:00AM	BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Apr-30-21 09:22AM	BioCryst Receives European Commission Approval of ORLADEYO (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients GlobeNewswire
Apr-29-21 05:03PM	Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to Decline Zacks
Apr-22-21 07:00AM	BioCryst to Report First Quarter 2021 Financial Results on May 6 GlobeNewswire
Apr-20-21 09:30AM	Is BCRX Stock A Buy or Sell? Insider Monkey
Apr-14-21 03:42PM	Why BioCryst Pharmaceuticals Stock Is Popping Today Motley Fool +5.21%
08:15AM	BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO (berotralstat) for Prophylactic Treatment of Hereditary Angioedema GlobeNewswire
Apr-08-21 01:19AM	The BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Is Up 421% And Shareholders Are Delighted Simply Wall St.
Apr-07-21 07:00AM	BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-24-21 12:16PM	BioCryst: Sometimes Good News Isnt Good Enough TipRanks
Mar-22-21 01:27PM	BioCryst Technical Levels To Watch Benzinga -10.88%
08:00AM	BioCrysts Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial GlobeNewswire
Mar-19-21 07:00AM	BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer GlobeNewswire
Mar-15-21 07:00AM	BioCryst to Host Virtual R&D Day on March 22, 2021 GlobeNewswire +6.65%

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stonehouse Jon P	President & CEO	Jan 11	Option Exercise	4.73	184,000	870,320	1,085,602	Jan 13 04:45 PM
Stonehouse Jon P	President & CEO	Jan 11	Sale	15.04	184,000	2,767,360	901,602	Jan 13 04:45 PM
Babu Yarlagadda S	Chief Discovery Officer	Dec 07	Option Exercise	4.73	62,000	293,260	245,156	Dec 09 04:38 PM
Babu Yarlagadda S	Chief Discovery Officer	Dec 07	Sale	12.20	30,100	367,220	215,056	Dec 09 04:38 PM
MILANO VINCENT	Director	Nov 24	Buy	12.19	7,500	91,425	17,500	Nov 24 06:35 PM
Doyle Anthony	Chief Financial Officer	Nov 23	Buy	12.48	35,258	440,020	93,719	Nov 24 06:35 PM
ABERCROMBIE GEORGE B	Director	Nov 15	Option Exercise	3.32	5,000	16,600	5,000	Nov 17 04:27 PM
ABERCROMBIE GEORGE B	Director	Nov 15	Sale	12.27	5,000	61,350	0	Nov 17 04:27 PM
Hutson Nancy J	Director	Oct 15	Option Exercise	3.46	105,000	363,450	170,073	Oct 19 04:21 PM
Hutson Nancy J	Director	Oct 15	Sale	15.40	105,000	1,617,000	65,073	Oct 19 04:21 PM
ABERCROMBIE GEORGE B	Director	Sep 15	Option Exercise	2.63	5,000	13,150	5,000	Sep 17 04:31 PM
ABERCROMBIE GEORGE B	Director	Sep 15	Sale	15.06	5,000	75,300	0	Sep 17 04:31 PM
LEE KENNETH B JR	Director	Sep 13	Option Exercise	3.22	15,000	48,300	30,252	Sep 15 04:26 PM
LEE KENNETH B JR	Director	Sep 13	Sale	15.35	6,000	92,100	24,252	Sep 15 04:26 PM
ABERCROMBIE GEORGE B	Director	Sep 10	Option Exercise	2.86	71,000	202,710	74,000	Sep 14 04:14 PM
ABERCROMBIE GEORGE B	Director	Sep 10	Sale	15.09	74,000	1,116,660	0	Sep 14 04:14 PM
ABERCROMBIE GEORGE B	Director	Jul 15	Option Exercise	2.63	5,000	13,150	8,000	Jul 19 04:39 PM
ABERCROMBIE GEORGE B	Director	Jul 15	Sale	15.69	5,000	78,450	3,000	Jul 19 04:39 PM
Hutson Nancy J	Director	Jun 10	Option Exercise	3.15	23,333	73,549	88,406	Jun 14 04:29 PM
Hutson Nancy J	Director	Jun 10	Sale	16.86	23,333	393,394	65,073	Jun 14 04:29 PM
Sheridan William P	Chief Medical Officer	May 28	Option Exercise	5.38	91,814	493,826	106,289	Jun 01 04:33 PM
Sheridan William P	Chief Medical Officer	May 28	Sale	15.02	91,814	1,379,046	14,475	Jun 01 04:33 PM
Sheridan William P	Chief Medical Officer	May 27	Option Exercise	5.27	71,759	378,114	86,234	Jun 01 04:33 PM
Sheridan William P	Chief Medical Officer	May 27	Sale	15.00	71,759	1,076,385	14,475	Jun 01 04:33 PM
ABERCROMBIE GEORGE B	Director	May 24	Option Exercise	2.63	6,667	17,534	9,667	May 26 04:12 PM
ABERCROMBIE GEORGE B	Director	May 24	Sale	13.90	6,667	92,671	3,000	May 26 04:12 PM
Barnes Alane P	Chief Legal Officer	May 12	Option Exercise	4.73	35,852	169,580	146,127	May 13 04:43 PM
Barnes Alane P	Chief Legal Officer	May 11	Option Exercise	4.14	102,780	425,442	213,055	May 13 04:43 PM
Barnes Alane P	Chief Legal Officer	May 11	Sale	12.04	102,780	1,237,471	110,275	May 13 04:43 PM
ABERCROMBIE GEORGE B	Director	May 10	Sale	12.70	7,000	88,900	3,000	May 12 05:02 PM
Jones Michael L	Exec. Director, Finance - PAO	Mar 18	Option Exercise	3.51	4,500	15,795	5,348	Mar 22 04:19 PM
Sheridan William P	Senior VP - CMO	Feb 22	Option Exercise	4.15	41,250	171,188	52,725	Feb 24 04:34 PM
Sheridan William P	Senior VP - CMO	Feb 22	Sale	11.57	41,250	477,262	11,475	Feb 24 04:34 PM
Babu Yarlagadda S	Senior VP - Drug Discovery	Feb 19	Option Exercise	4.15	50,000	207,500	205,587	Feb 23 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience